Changes in Beneficial Ownership · 4
Relay Therapeutics, Inc.
RLAYNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-08
- Issuer
- Relay Therapeutics, Inc.
- Issuer CIK
- 0001812364
- Trading symbol
- RLAY
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Bergstrom Donald A
- Reporting owner CIK
- 0001709772
- Relationship
- Officer
- Officer title
- President, R&D
- Address
- C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-08 | S · Form 4[F1] | 8,530 | D | 18.97[F2] | 399,130[F3] | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.↩ 1
- F2
- This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1
- F3
- Includes 10,025 shares underlying restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Soo-Yeun Lim, as Attorney-in-Fact
- Date
- 2026-09-09
Company context
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs